

DEPARTMENT OF COMMERCE **Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR: ATTORNEY DOCKET NO 09/250,769 02/15/99 OSTLUND R P03496US1 **EXAMINER** HM12/0526 EDMUND J SEASE JORDAN, K 801 GRAND AVENUE **ART UNIT** PAPER NUMBER SUITE 3200 DES MOINES IA 50209 1614 DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

05/26/99

Application No.

Applicant(s)

09/250,769

Examiner

Office Action Summary

Kimberly Jordan

Group Art Unit 1614

Ostlund



Responsive to communication(s) filed on	
☐ This action is FINAL .	
Since this application is in condition for allowance except for f in accordance with the practice under Ex parte Quayle, 1935	
A shortened statutory period for response to this action is set to dis longer, from the mailing date of this communication. Failure to application to become abandoned. (35 U.S.C. § 133). Extension 37 CFR 1.136(a).	respond within the period for response will cause the
Disposition of Claims	
X Claim(s) 1-16	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	is/are allowed.
Claim(s)	
☐ Claims	
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Drawing	Review, PTO-948.
The drawing(s) filed on is/are objected	to by the Examiner.
☐ The proposed drawing correction, filed on	is 🗖 approved 🗖 disapproved.
$\hfill\Box$ The specification is objected to by the Examiner.	
\square The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priority un	nder 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of t	he priority documents have been
☐ received.	
☐ received in Application No. (Series Code/Serial Numb	er)
\square received in this national stage application from the In	ternational Bureau (PCT Rule 17.2(a)).
*Certified copies not received:	•
☐ Acknowledgement is made of a claim for domestic priority	under 35 U.S.C. § 119(e).
Attachment(s)	
☐ Notice of References Cited, PTO-892	
	s)2
☐ Interview Summary, PTO-413	. , _
Notice of Draftsperson's Patent Drawing Review, PTO-948	
☐ Notice of Informal Patent Application, PTO-152	
	KIMBÉRLY JORDAN PRIMARY EXAMINER
	GROUP_1299-
SEE OFFICE ACTION ON TH	E FOLLOWING PAGES 1610

1610

Art Unit: 1614

Claims 1-16 are presented for examination.

Claim 14 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Regarding claim 14, the phrase "including" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Straub (AA). The claims appear to be drawn to a composition and method of lowering cholesterol absorption by administering a composition or food product containing sitostanol and an alkali metal reaction product of lactic acid and a fatty acid as an emulsifier. Straub teaches sitostanol to be useful in lowering cholesterol absorption (see abstract). Straub also teaches that sitostanol may be formulated with emulsifiers such as sodium lauryl sulfate (see column 6, lines 3-22). The claims differ from the cited reference in claiming the lactic acid esters of the fatty acid salts. To substitute the lactic acid esters would have been obvious because fatty acid salts of lactic acid esters such as sodium stearoyl-2-lactylate are well known emulsifiers and would be expected to work as well as sodium lauryl sulfate. Furthermore, the sodium stearoyl-2-lactylate has not been

Art Unit: 1614

demonstrated to produce unexpected results in comparison to the closest prior art (i.e., sodium lauryl sulfate). Thus, the claims fail to patentably distinguish over the state of the art as represented by the cited reference.

No claims are allowed.

Any inquiry concerning this communication should be directed to Kimberly Jordan at telephone number (703) 308-4611.

KIMBERLY JORDAN PRIMARY EXAMINER GROUP_1200-

1610

JORDAN

May 24, 1999